Medical imaging, such as computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET), plays a vital role for the decision-making in oncologic management. In clinical practice, imaging-derived tumor metrics are routinely applied in oncologic management as an imaging biomarker. For example, the Response Evaluation Criteria in Solid Tumors (RECIST) are commonly used for tumor treatment response evaluation based on the dynamic changes in tumor size. However, the current cross-sectional images are interpreted qualitatively for lesion characterization, treatment response evaluation and prognostic prediction by highly trained radiologists, which has increasingly apparent limitations. Therefore, there is a demanding shift toward more quantitative imaging interpretation.
